Limiting research on molecular targeted therapies in advanced solid cancers: beyond a cost-effectiveness ratio analysis

Biomark Med. 2019 Aug;13(11):887-890. doi: 10.2217/bmm-2019-0216. Epub 2019 Jul 18.

Authors

Andrea Nicolini¹, Paola Ferrari¹, Angelo Carpi²

Affiliations

¹ Department of Oncology, Transplantations & New Technologies in Medicine, University of Pisa, Italy.
² Department of Clinical & Experimental Medicine, University of Pisa, Italy.

PMID: 31317773
DOI: 10.2217/bmm-2019-0216

No abstract available

Keywords: drug repurposing; financial resources; solid cancer; target therapy; therapeutic strategy.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / economics
Antineoplastic Agents / therapeutic use
Biomarkers / blood
Cost-Benefit Analysis
Drug Repositioning / economics
Humans
Molecular Targeted Therapy* / economics
Neoplasms / blood
Neoplasms / drug therapy*
Neoplasms / economics

Substances

Antineoplastic Agents
Biomarkers